Conversion Labs: Telehealth Subscriptions

By -

 

  • Conversion Labs was highlighted in a bull call by Citron Research.
  • The company is building a DTC health and wellness platform focused on subscription services.
  • Q4 revenues surged 265% to $13.6 million.
  • The stock is cheap compared to other telehealth brands trading at less than 5x EV/S multiples.
  • This idea was discussed in more depth with members of my private investing community, Out Fox The Street. Get started today »

The telehealth space was hot in 2020 and Conversion Labs (CVLB) is playing perfectly into this trend. The company is quickly ramping up some new direct-to-consumer subscription services while building a telehealth platform for future products. The stock is appealing here after a notable firm made a bullish case on the stock.

Read the full article on Seeking Alpha. 

Update - March 18

A couple of weeks ago, LifeMD predicted Q1 revenue to reach $17 million. After the close, $HIMS reported a solid revenue beat for Q4. $LFMD reports after the close on the 29th. 

-Him & Hers Health (NYSE:HIMS): Q4 GAAP EPS of -$0.07 beats by $0.13.
-Revenue of $41.47M (+67.4% Y/Y) beats by $4.47M.


Disclosure: No positioned mentioned. Please review the disclaimer page for more details. 

Comments

Post a Comment

Popular posts from this blog

Aurora Cannabis: Deal Or No Deal

By -
Aurora Cannabis was left out of the major deal making in 2018. The cannabis company updated FQ2 guidance to revenues of $50 to $55 million with a continued focus on pure production growth. The stock is down as the market is becoming less impressed with commodity farming operations due to the prime Oregon example. The stock is below key resistance at $5.40 as medical cannabis patient totals failed to impress. As the end of 2018 came and went,   Aurora Cannabis   ( ACB ) was a notable absentee from the deal making in the cannabis market. Just about all of the other major Canadian cannabis players got large investments or signed up powerful partnerships, but the related stocks didn't generally maintain rallies following the deals. Based on the early legalization data in Canada and Oregon, the best option for Aurora Cannabis might actually be selling production capacity while the Canadian market remains hot. Read the full article on Seeking Alpha.  Disclosure: No
Read more

Skillz: Back To Earth

By -
Image
  Wolfpack Research released a short report on Skillz. The recently closed SPAC deal was irrationally priced in the stock market with the market cap soaring above $20 billion at the highs. The company must maintain 2021 revenue targets of $366 million despite the headwinds in mobile gaming. Investors must avoid this stock due to valuation and especially if Wolfpack Research is accurate on the upcoming revenue misses. This idea was discussed in more depth with members of my private investing community, Out Fox The Street.  Learn More » The upcoming  Skillz  ( SKLZ ) earnings report is important for not only the stock, but also the cooling SPAC space. A lot of the blank-check companies have made business combinations based on aggressive 2025+ revenue targets, yet very few of these companies have reported earnings since going public. The real-money gaming platform was already an extremely expensive stock before Wolfpack Research hit the stock with a  report  suggesting the revenue targets
Read more